These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 28733195)

  • 1. The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics.
    Rosenbaum JN; Weisman P
    Am J Pathol; 2017 Oct; 187(10):2185-2198. PubMed ID: 28733195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next-Generation Breast Cancer Omics.
    Coleman WB
    Am J Pathol; 2017 Oct; 187(10):2130-2132. PubMed ID: 28822804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Omics-Based Strategies in Precision Medicine: Toward a Paradigm Shift in Inborn Errors of Metabolism Investigations.
    Tebani A; Afonso C; Marret S; Bekri S
    Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27649151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel personalized pathway-based metabolomics models reveal key metabolic pathways for breast cancer diagnosis.
    Huang S; Chong N; Lewis NE; Jia W; Xie G; Garmire LX
    Genome Med; 2016 Mar; 8(1):34. PubMed ID: 27036109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiomics Data Triangulation for Asthma Candidate Biomarkers and Precision Medicine.
    Pecak M; Korošec P; Kunej T
    OMICS; 2018 Jun; 22(6):392-409. PubMed ID: 29927718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
    Campbell MR
    Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolomics Biomarkers for Breast Cancer.
    Günther UL
    Pathobiology; 2015 Sep; 82(3-4):153-65. PubMed ID: 26330356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining tissue transcriptomics and urine metabolomics for breast cancer biomarker identification.
    Nam H; Chung BC; Kim Y; Lee K; Lee D
    Bioinformatics; 2009 Dec; 25(23):3151-7. PubMed ID: 19783829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies.
    Beaver JA; Tzou A; Blumenthal GM; McKee AE; Kim G; Pazdur R; Philip R
    Clin Cancer Res; 2017 Mar; 23(6):1368-1372. PubMed ID: 27993967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome.
    Budczies J; Denkert C
    Recent Results Cancer Res; 2016; 207():157-75. PubMed ID: 27557538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imaging and the completion of the omics paradigm in breast cancer.
    Leithner D; Horvat JV; Ochoa-Albiztegui RE; Thakur S; Wengert G; Morris EA; Helbich TH; Pinker K
    Radiologe; 2018 Nov; 58(Suppl 1):7-13. PubMed ID: 29947931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolving 'omics' technologies for diagnostics of head and neck cancer.
    Nagaraj NS
    Brief Funct Genomic Proteomic; 2009 Jan; 8(1):49-59. PubMed ID: 19273537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of Companion Diagnostics.
    Mankoff DA; Edmonds CE; Farwell MD; Pryma DA
    Semin Nucl Med; 2016 Jan; 46(1):47-56. PubMed ID: 26687857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Challenges and opportunities for next-generation sequencing in companion diagnostics.
    Lin E; Chien J; Ong FS; Fan JB
    Expert Rev Mol Diagn; 2015 Feb; 15(2):193-209. PubMed ID: 25249308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
    Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
    Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ProfileDB: a resource for proteomics and cross-omics biomarker discovery.
    Bauer C; Glintschert A; Schuchhardt J
    Biochim Biophys Acta; 2014 May; 1844(5):960-6. PubMed ID: 24270047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast cancer management: opportunities and barriers to an individualized approach.
    Perez EA
    Oncologist; 2011; 16 Suppl 1():20-2. PubMed ID: 21278437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Companion diagnostics: a regulatory perspective from the last 5 years of molecular companion diagnostic approvals.
    Roscoe DM; Hu YF; Philip R
    Expert Rev Mol Diagn; 2015; 15(7):869-80. PubMed ID: 26109316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.